1-4 of 4
Thomas Philipp
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease

Alexander Röth, Andreas Hüttmann, Russell P. Rother, Ulrich Dührsen, Thomas Philipp
Journal: Blood
Blood (2009) 113 (16): 3885–3886.
https://doi.org/10.1182/blood-2009-01-196329
Published: 2009
Journal Articles

Long-Term Efficacy of the Terminal Complement Inhibitor Eculizumab in a Patient with Cold Agglutinin Disease (CAD)

Alexander Roeth, MD, Andreas Huettmann, MD, Ulrich Duehrsen, MD, Thomas Philipp, MD
Journal: Blood
Blood (2008) 112 (11): 2882.
https://doi.org/10.1182/blood.V112.11.2882.2882
Published: 2008
Journal Articles

Successful Treatment of Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor Eculizumab.

Jens Nuernberger, Oliver Witzke, Russell P. Rother, PhD, Thomas Philipp, Udo Vester, Hideo Baba, Lothar Bernd Zimmerhackl, Andreas Kribben
Journal: Blood
Blood (2008) 112 (11): 2294.
https://doi.org/10.1182/blood.V112.11.2294.2294
Published: 2008
Journal Articles

Effects of Renal Impairment on the Pharmacology of Rivaroxaban (BAY 59-7939) - An Oral, Direct, Factor Xa Inhibitor.

Atef Halabi, MD, Haidar Maatouk, MD, Norbert Klause, MD, Volkmar Lufft, MD, Dagmar Kubitza, MD, Michael Zuehlsdorf, PhD, Michael Becka, PhD, Wolfgang Mueck, PhD, Rafael Schäfers, MD, Dominic Wand, Thomas Philipp, MD, Heike Bruck, MD
Journal: Blood
Blood (2006) 108 (11): 913.
https://doi.org/10.1182/blood.V108.11.913.913
Published: 2006